Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 10.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,662 shares of the pharmaceutical company’s stock after acquiring an additional 159 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Vertex Pharmaceuticals were worth $481,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of VRTX. LSV Asset Management increased its stake in shares of Vertex Pharmaceuticals by 206.3% in the 1st quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 3,200 shares during the last quarter. Synovus Financial Corp increased its stake in shares of Vertex Pharmaceuticals by 9.6% in the 1st quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock worth $1,759,000 after acquiring an additional 590 shares during the last quarter. Cibc World Market Inc. increased its stake in shares of Vertex Pharmaceuticals by 69.4% in the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock worth $1,728,000 after acquiring an additional 2,713 shares during the last quarter. Sei Investments Co. increased its stake in shares of Vertex Pharmaceuticals by 28.4% in the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock worth $11,756,000 after acquiring an additional 9,761 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Vertex Pharmaceuticals by 4.0% in the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Cowen raised their target price on Vertex Pharmaceuticals from $315.00 to $330.00 in a research note on Friday, October 28th. StockNews.com started coverage on Vertex Pharmaceuticals in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Piper Sandler raised their price objective on Vertex Pharmaceuticals from $288.00 to $293.00 in a research report on Sunday, October 16th. Barclays raised their price objective on Vertex Pharmaceuticals from $307.00 to $313.00 and gave the stock an “overweight” rating in a research report on Friday, October 28th. Finally, JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $319.00 to $327.00 and gave the stock an “overweight” rating in a research report on Monday, October 24th. Seven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $308.90.

Insider Buying and Selling

In related news, EVP David Altshuler sold 1,303 shares of the business’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $303.04, for a total transaction of $394,861.12. Following the completion of the sale, the executive vice president now owns 36,077 shares in the company, valued at $10,932,774.08. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, EVP David Altshuler sold 1,303 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $303.04, for a total transaction of $394,861.12. Following the transaction, the executive vice president now owns 36,077 shares of the company’s stock, valued at $10,932,774.08. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 621 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $310.00, for a total value of $192,510.00. Following the transaction, the director now directly owns 4,040 shares in the company, valued at approximately $1,252,400. The disclosure for this sale can be found here. 0.40% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $300.94 on Tuesday. The stock has a 50-day simple moving average of $303.47 and a 200-day simple moving average of $295.71. The stock has a market capitalization of $77.25 billion, a PE ratio of 23.73, a PEG ratio of 2.35 and a beta of 0.46. Vertex Pharmaceuticals Incorporated has a 1 year low of $221.69 and a 1 year high of $324.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.55 and a current ratio of 4.70.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last posted its earnings results on Thursday, October 27th. The pharmaceutical company reported $3.62 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.31. The firm had revenue of $2.33 billion during the quarter, compared to analysts’ expectations of $2.23 billion. Vertex Pharmaceuticals had a return on equity of 29.65% and a net margin of 37.62%. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 13.03 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.